Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioCardia, Inc is a biotechnology business based in the US. BioCardia shares (BCDA) are listed on the NASDAQ and all prices are listed in US Dollars. BioCardia employs 20 staff and has a trailing 12-month revenue of around USD$314,000.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$2.65 |
---|---|
52-week range | USD$1.91 - USD$6.5 |
50-day moving average | USD$2.9106 |
200-day moving average | USD$2.5439 |
Wall St. target price | USD$12.88 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-3.2 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.65 from 2020-12-09
1 week (2021-01-09) | N/A |
---|---|
1 month (2020-12-18) | -25.56% |
3 months (2020-10-16) | 15.22% |
6 months (2020-07-17) | 11.34% |
1 year (2020-01-17) | -48.44% |
---|---|
2 years (2019-01-18) | 96.30% |
3 years (2018-01-18) | 3.01 |
5 years (2016-01-16) | N/A |
Revenue TTM | USD$314,000 |
---|---|
Gross profit TTM | USD$-8,210,000 |
Return on assets TTM | -96.41% |
Return on equity TTM | -333.43% |
Profit margin | 0% |
Book value | $0.331 |
Market capitalisation | USD$55.4 million |
TTM: trailing 12 months
There are currently 12,431 BioCardia shares held short by investors – that's known as BioCardia's "short interest". This figure is 10.4% up from 11,265 last month.
There are a few different ways that this level of interest in shorting BioCardia shares can be evaluated.
BioCardia's "short interest ratio" (SIR) is the quantity of BioCardia shares currently shorted divided by the average quantity of BioCardia shares traded daily (recently around inf billion). BioCardia's SIR currently stands at 0. In other words for every 100,000 BioCardia shares traded daily on the market, roughly 0 shares are currently held short.
However BioCardia's short interest can also be evaluated against the total number of BioCardia shares, or, against the total number of tradable BioCardia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCardia's short interest could be expressed as 0% of the outstanding shares (for every 100,000 BioCardia shares in existence, roughly 0 shares are currently held short) or 0.0015% of the tradable shares (for every 100,000 tradable BioCardia shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioCardia.
Find out more about how you can short BioCardia stock.
We're not expecting BioCardia to pay a dividend over the next 12 months.
BioCardia's shares were split on a 1:9 basis on 6 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioCardia shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for BioCardia shares which in turn could have impacted BioCardia's share price.
Over the last 12 months, BioCardia's shares have ranged in value from as little as $1.91 up to $6.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCardia's is 2.0343. This would suggest that BioCardia's shares are significantly more volatile than the average for this exchange and represent a higher risk.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.